Literature DB >> 30108886

Imidazoles as potential anticancer agents.

Imran Ali1, Mohammad Nadeem Lone1, Haasan Y Aboul-Enein2.   

Abstract

Cancer is a black spot on the face of humanity in this era of science and technology. Presently, several classes of anticancer drugs are available in the market, but issues such as toxicity, low efficacy and solubility have decreased the overall therapeutic indices. Thus, the search for new promising anticancer agents continues, and the battle against cancer is far from over. Imidazole is an aromatic diazole and alkaloid with anticancer properties. There is considerable interest among scientists in developing imidazoles as safe alternatives to anticancer chemotherapy. The present article describes the structural, chemical, and biological features of imidazoles. Several classes of imidazoles as anticancer agents based on their mode of action have been critically discussed. A careful observation has been made into pharmacologically active imidazoles with better or equal therapeutic effects compared to well-known imidazole-based anticancer drugs, which are available on the market. A brief discussion of the toxicities of imidazoles has been made. Finally, the current challenges and future perspectives of imidazole based anticancer drug development are conferred.

Entities:  

Year:  2017        PMID: 30108886      PMCID: PMC6084102          DOI: 10.1039/c7md00067g

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  172 in total

Review 1.  New dermatological agents for the treatment of psoriasis.

Authors:  S M Thacher; J Vasudevan; K Y Tsang; S Nagpal; R A Chandraratna
Journal:  J Med Chem       Date:  2001-02-01       Impact factor: 7.446

2.  Synthesis and inhibitory activity of new benzimidazole derivatives against Burkitt's lymphoma promotion.

Authors:  Mostafa M Ramla; Mohamed A Omar; H Tokuda; Hoda I El-Diwani
Journal:  Bioorg Med Chem       Date:  2007-04-10       Impact factor: 3.641

3.  Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.

Authors:  Julianne L Holleran; Robert A Parise; Archibong E Yellow-Duke; Merrill J Egorin; Julie L Eiseman; Joseph M Covey; Jan H Beumer
Journal:  J Pharm Biomed Anal       Date:  2010-02-23       Impact factor: 3.935

4.  Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.

Authors:  J S Lee; R A Newman; S M Lippman; M H Huber; T Minor; M N Raber; I H Krakoff; W K Hong
Journal:  J Clin Oncol       Date:  1993-05       Impact factor: 44.544

5.  Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.

Authors:  Dan Niculescu-Duvaz; Ion Niculescu-Duvaz; Bart M J M Suijkerbuijk; Delphine Ménard; Alfonso Zambon; Arnaud Nourry; Lawrence Davies; Helen A Manne; Frank Friedlos; Lesley Ogilvie; Douglas Hedley; Andrew K Takle; David M Wilson; Jean-Francois Pons; Tom Coulter; Ruth Kirk; Neus Cantarino; Steven Whittaker; Richard Marais; Caroline J Springer
Journal:  Bioorg Med Chem       Date:  2010-06-15       Impact factor: 3.641

6.  Design, synthesis and biological evaluation of novel hybrid compounds of imidazole scaffold-based 2-benzylbenzofuran as potent anticancer agents.

Authors:  Xue-Quan Wang; Lan-Xiang Liu; Yan Li; Cheng-Jun Sun; Wen Chen; Liang Li; Hong-Bin Zhang; Xiao-Dong Yang
Journal:  Eur J Med Chem       Date:  2013-01-03       Impact factor: 6.514

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates.

Authors:  Mohamed S Gomaa; Andrew S T Lim; S C Wilson Lau; Ann-Marie Watts; Nicola A Illingworth; Caroline E Bridgens; Gareth J Veal; Christopher P F Redfern; Andrea Brancale; Jane L Armstrong; Claire Simons
Journal:  Bioorg Med Chem       Date:  2012-08-30       Impact factor: 3.641

Review 9.  Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.

Authors:  A Jordan; J A Hadfield; N J Lawrence; A T McGown
Journal:  Med Res Rev       Date:  1998-07       Impact factor: 12.944

10.  New imidazole alkaloids from the Indonesian sponge Leucetta chagosensis.

Authors:  Wafaa Hassan; RuAngelie Edrada; Rainer Ebel; Victor Wray; Albrecht Berg; Rob van Soest; Sumali Wiryowidagdo; Peter Proksch
Journal:  J Nat Prod       Date:  2004-05       Impact factor: 4.050

View more
  29 in total

1.  Regioselective Synthesis of 2-Aryl-5-cyano-1-(2-hydroxyaryl)-1H-imidazole-4-carboxamides Self-Assisted by a 2-Hydroxyaryl Group.

Authors:  Fábio Pedroso de Lima; Emilio Lence; Pilar Suárez de Cepeda; Carla Correia; M Alice Carvalho; Concepción González-Bello; M Fernanda Proença
Journal:  ACS Omega       Date:  2022-06-24

2.  Anticancer effects of imidazole nucleus in hepatocellular carcinoma cell lines via the inhibition of AKT and ERK1/2 signaling pathways.

Authors:  Erkan Kahraman; Erdem Göker
Journal:  Mol Biol Rep       Date:  2022-02-28       Impact factor: 2.742

3.  Epigenetic modulation and apoptotic induction by a novel imidazo-benzamide derivative in human lung adenocarcinoma cells.

Authors:  Amrutha Arjunan; Sankar Pajaniradje; Arul Prakash Francis; Srividya Subramanian; Sathyapriya Chandramohan; D Parthasarathi; Ayyiliath M Sajith; M Syed Ali Padusha; P P Mathur; Rukkumani Rajagopalan
Journal:  Daru       Date:  2021-10-12       Impact factor: 4.088

4.  Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging.

Authors:  Li Wang; Hui Wang; Kun Shen; Hyejin Park; Tao Zhang; Xuedan Wu; Mei Hu; Hong Yuan; Yue Chen; Zhanhong Wu; Qiu Wang; Zibo Li
Journal:  J Med Chem       Date:  2021-04-26       Impact factor: 7.446

5.  Experimental study on preparation and anti-tumor efficiency of nanoparticles targeting M2 macrophages.

Authors:  Zheng Zeng; Yu Liu; Qinglian Wen; Yixian Li; Jing Yu; Qiang Xu; Wenwu Wan; Yu He; Chen Ma; Yan Huang; Helin Yang; Ou Jiang; Fuyu Li
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

6.  Synthesis and Anticancer and Antimicrobial Evaluation of Novel Ether-linked Derivatives of Ornidazole.

Authors:  Sevil Şenkardeş; Necla Kulabaş; Özlem Bingöl Özakpinar; Sadık Kalayci; Fikrettin Şahin; İlkay Küçükgüzel; Ş Güniz Küçükgüzel
Journal:  Turk J Pharm Sci       Date:  2020-02-19

7.  Synthesis and photophysical properties of benzoxazolyl-imidazole and benzothiazolyl-imidazole conjugates.

Authors:  Hsing-Yu Chen; Chen-Chen Yao; Tzu-Yu Tseng; Yao-Chun Yeh; He-Shin Huang; Mei-Yu Yeh
Journal:  RSC Adv       Date:  2021-12-17       Impact factor: 3.361

8.  Evaluation of the Anticancer Activities of Novel Transition Metal Complexes with Berenil and Nitroimidazole.

Authors:  Robert Czarnomysy; Dominika Radomska; Anna Muszyńska; Justyna Magdalena Hermanowicz; Izabela Prokop; Anna Bielawska; Krzysztof Bielawski
Journal:  Molecules       Date:  2020-06-21       Impact factor: 4.411

9.  Transition metal-free oxidative and deoxygenative C-H/C-Li cross-couplings of 2H-imidazole 1-oxides with carboranyl lithium as an efficient synthetic approach to azaheterocyclic carboranes.

Authors:  Lidia A Smyshliaeva; Mikhail V Varaksin; Pavel A Slepukhin; Oleg N Chupakhin; Valery N Charushin
Journal:  Beilstein J Org Chem       Date:  2018-10-12       Impact factor: 2.883

10.  Synthesis of 99mTc-labeled 2-Mercaptobenzimidazole as a novel radiotracer to diagnose tumor hypoxia.

Authors:  Syed Faheem Askari Rizvi; Haixia Zhang; Sajid Mehmood; Mahmoud Sanad
Journal:  Transl Oncol       Date:  2020-08-28       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.